Newbury Pharmaceuticals AB (publ) announce the expansion of its portfolio with Daptomycin and Linezolid with already granted Marketing Authorizations (MA) in Sweden. Both products are sourced from new partners to Newbury and based on a Distribution and Marketing agreement where Newbury will perform the commercialization in the territory.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.3 SEK | -2.37% | -0.60% | +7.49% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+7.49% | 7.82M | |
-13.57% | 8.02B | |
+25.86% | 1.2B | |
-8.03% | 356M | |
+7.51% | 282M | |
+8.89% | 225M | |
-48.54% | 77.42M | |
+28.21% | 62.34M |
- Stock Market
- Equities
- NEWBRY Stock
- News Newbury Pharmaceuticals AB
- Newbury Expands Its Portfolio with Two Ready to Launch Products